Blaustein Robert
SEC insider (Form 3/4/5 filer). CIK 0002053149. Chief Development Officer at Edgewise Therapeutics, Inc. (EWTX). 4 reported Form 4/5 transactions since Sep 2024; latest on Aug 12, 2025. Located in BOULDER, CO.
Companies Blaustein Robert has filed insider reports for
- Edgewise Therapeutics, Inc. (EWTX): Officer, Chief Development Officer
Blaustein Robert
CIK: 0002053149
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Edgewise Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 12, 2025EWTX
Edgewise Therapeutics, Inc.
AwardDirectRestricted Stock Units
17.5K shares- - Aug 12, 2025EWTX
Edgewise Therapeutics, Inc.
AwardDirectStock Options (Right to buy)
105K shares- - Jan 21, 2025EWTX
Edgewise Therapeutics, Inc.
AwardDirectRestricted Stock Units
30K shares- - Jan 21, 2025EWTX
Edgewise Therapeutics, Inc.
AwardDirectStock Options (Right to buy)
160K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Award Restricted Stock Units | 17,500 | - | - | Direct |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Award Stock Options (Right to buy) | 105,000 | - | - | Direct |
| Jan 21, 2025 | EWTX Edgewise Therapeutics, Inc. | Award Restricted Stock Units | 30,000 | - | - | Direct |
| Jan 21, 2025 | EWTX Edgewise Therapeutics, Inc. | Award Stock Options (Right to buy) | 160,000 | - | - | Direct |
1-4 of 4 transactions